Molecule Structure

Scientific Name

Asciminib

Description of the Drug

Asciminib is an inhibitor of ABL/BCR-ABL1 tyrosine kinase for the treatment of patients with Philadelphia chromosome-positive CML, including those with the T315I mutation.

Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB12597

Brand Name(s)

Not Available

Company Owner(s)

Novartis Pharmaceuticals Corp

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
Tyrosine-protein kinase ABL SINGLE PROTEIN INHIBITOR CHEMBL1862
Bcr/Abl fusion protein CHIMERIC PROTEIN INHIBITOR CHEMBL2096618

Unichem Links

SureChEMBL SCHEMBL15388306
PharmGKB PA166268841
DrugBank DB12597
PubChem 72165228
PDBe AY7
BindingDB 50459091
ChemicalBook CB23133462
Guide to Pharmacology 8962
ZINC ZINC000150275965